Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients

Table 2 Results of the pairwise comparisons of individual hepatic fibrosis stages with respect to log₂ MFAP4 values after significant ANOVA result

Comparison^a	Difference^b	Lower bound^c	Upper bound^c	p value^d
F1–F0	0.1924	−0.1114	0.4962	0.4144
F2–F0	0.4386	0.1188	0.7584	0.0018
F3–F0	1.1168	0.7351	1.4984	3.43E−10
F4–F0	1.4277	1.0461	1.8092	3.43E−10
F2–F1	0.2462	−0.0287	0.5211	0.1036
F3–F1	0.9244	0.5796	1.2693	3.51E−10
F4–F1	1.2353	0.8903	1.5802	3.43E−10
F3–F2	0.6782	0.3191	1.0373	3.280E−6
F4–F2	0.9891	0.6300	1.3482	3.45E−10
F4–F3	0.3109	−0.1042	0.7260	0.2438

^aPairwise comparison between individual fibrosis stages
^bEstimated difference between true mean values of individual groups (log₂ U/ml)
^cUpper respectively lower bound of the 95 % confidence interval of difference (log₂ U/ml)
^dAdjusted p value according to Tukey’s‚ honest significant difference’ post hoc test

ISSN: 1479-5876